论文部分内容阅读
骨肉瘤是一种主要侵犯儿童和青少年的恶性骨肿瘤。在骨肉瘤患者中肿瘤局限性患者的5年生存率为70%,而发生了肿瘤转移的患者的5年生存率却只有20%～30%[1]。超过90%的肿瘤患者的死亡都归因于肿瘤转移[2]。肿瘤转移是一个复杂的过程,而每一个过程都可以成为一个治疗的靶点。在过去的10年间,对于骨肉瘤的转移机制已经做了很多深入的研究,而近来发现Ezrin与骨肉瘤转移及预后有密切的关系,所以深入研究Ezrin在骨肉瘤中的作用及机制对骨肉瘤的防治有重大意义。
Osteosarcoma is a malignant bone tumor that mainly affects children and adolescents. The 5-year survival rate of patients with localized tumors is 70% in patients with osteosarcoma, compared to 20% to 30% in patients with metastatic tumors [1]. More than 90% of cancer deaths are due to tumor metastasis [2]. Tumor metastasis is a complex process, and every process can be a therapeutic target. In the past 10 years, many studies have been done on the mechanism of osteosarcoma metastasis. Recently, Ezrin has been found to be closely related to the metastasis and prognosis of osteosarcoma. Therefore, the role of Ezrin in osteosarcoma and the mechanism of osteosarcoma The prevention and treatment is of great significance.